HomeCompareHLUYY vs DGRO

HLUYY vs DGRO: Dividend Comparison 2026

HLUYY yields 21.52% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLUYY wins by $48.5K in total portfolio value
10 years
HLUYY
HLUYY
● Live price
21.52%
Share price
$22.00
Annual div
$4.73
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$7,902.94
Full HLUYY calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — HLUYY vs DGRO

📍 HLUYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLUYYDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLUYY + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLUYY pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLUYY
Annual income on $10K today (after 15% tax)
$1,829.43/yr
After 10yr DRIP, annual income (after tax)
$6,717.50/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, HLUYY beats the other by $6,513.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLUYY + DGRO for your $10,000?

HLUYY: 50%DGRO: 50%
100% DGRO50/50100% HLUYY
Portfolio after 10yr
$55.9K
Annual income
$4,071.45/yr
Blended yield
7.29%
📊

Analyst Conviction Gap

Where Wall Street is split right now

HLUYY
Analyst Ratings
1
Hold
Consensus: Hold
DGRO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLUYY buys
0
DGRO buys
0
No recent congressional trades found for HLUYY or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLUYYDGRO
Forward yield21.52%2.13%
Annual dividend / share$4.73$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$80.1K$31.6K
Annual income after 10y$7,902.94$239.96
Total dividends collected$47.3K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: HLUYY vs DGRO ($10,000, DRIP)

YearHLUYY PortfolioHLUYY Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$12,852$2,152.27$11,293$213.22+$1.6KHLUYY
2$16,337$2,585.20$12,730$217.32+$3.6KHLUYY
3$20,552$3,071.18$14,326$221.10+$6.2KHLUYY
4$25,601$3,610.76$16,098$224.56+$9.5KHLUYY
5$31,597$4,203.63$18,064$227.74+$13.5KHLUYY
6$38,657$4,848.69$20,246$230.65+$18.4KHLUYY
7$46,908$5,544.07$22,666$233.30+$24.2KHLUYY
8$56,478$6,287.15$25,349$235.73+$31.1KHLUYY
9$67,506$7,074.71$28,325$237.94+$39.2KHLUYY
10$80,135$7,902.94$31,624$239.96+$48.5KHLUYY

HLUYY vs DGRO: Complete Analysis 2026

HLUYYStock

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Full HLUYY Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this HLUYY vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLUYY vs SCHDHLUYY vs JEPIHLUYY vs OHLUYY vs KOHLUYY vs MAINHLUYY vs VIGHLUYY vs NOBLHLUYY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.